Nirma had entered into a share purchase agreement dated September 21, 2023, with the Glenmark Pharmaceuticals and the target company Glenmark Life Sciences, whereby it agreed to acquire 9,18,95,379 shares, representing 74.84 per cent of the Voting Share Capital, subject to and in accordance with the terms and conditions contained in the SPA.